Capricor Therapeutics is trading at $6.61, up 6.10%, with no clearly confirmed catalyst directly explaining the October 29 move. - An October 29 report discussed final HOPE-2 results, including reduced upper-limb function decline versus placebo; it did not establish that the report caused the share rise. - The move was against the broader market’s lower direction, so the supplied market context does not explain the gain. - Volume or unusual trading activity was not verified.